20
Aurobindo Pharma Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ATOVAQUONE USP, with a corresponding US DMF Number 31675.
Remarkably, this DMF maintains an Active status since its submission on April 25, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 10, 2017, and payment made on April 24, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II